Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT04068896

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

Sponsor: NGM Biopharmaceuticals, Inc

Conditions Bladder Cancer Colorectal Cancer Esophageal Cancer Gastric Cancer Head Neck Squamous Cell Carcinoma Melanoma Metastatic Castration-resistant Prostate Cancer Non-small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer

Interventions NGM120 100mg NGM120 100mg Q3W NGM120 100mg with Gemcitabine and Abraxane NGM120 30mg NGM120 30mg with Gemcitabine and Abraxane Placebo

Updated 15 times since 2019 Last updated: May 23, 2025 Started: Oct 16, 2019 Primary completion: Sep 21, 2023 Completion: Jan 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04068896, this PHASE1/PHASE2 trial focuses on Bladder Cancer and Colorectal Cancer and remains completed. Sponsored by NGM Biopharmaceuticals, Inc, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Jun 2025 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Jun 2025 [monthly]

Completed PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Status: Active Not Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 10 earlier versions

Jun 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Sep 2022 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2021 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Mar 2020 — Aug 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Mar 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2019 — Dec 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NGM Biopharmaceuticals, Inc

Data source: NGM Biopharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Houston, United States , Los Angeles, United States , Miami, United States , Milwaukee, United States and 9 more locations